Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
October 2, 2025

Supplementary Figure S1 from Targeting Myeloid Trem2 Reprograms the Immunosuppressive Niche and Potentiates Checkpoint Immunotherapy in NASH-Driven Hepatocarcinogenesis

View Full Paper
Ask AI
Bookmark
Share

Authors

ZWZiyi WangYZYu ZhangXLXiangdong Li

Discussion

Loading...

Member takes

Overview

Targeting Trem2 promotes an immunosuppressive phenotype in NASH, suggesting enhanced checkpoint immunotherapy effectiveness.

Key Points

  • Up-regulation of Trem2 promotes an immunosuppressive phenotype in NASH, aiding cancer progression.
  • Trem2 targeting may enhance checkpoint immunotherapy against hepatocarcinogenesis driven by NASH.
  • This research identifies mechanisms in the immunosuppressive niche, highlighting Trem2's role.
  • Understanding Trem2 interactions could lead to innovative therapies for liver cancer linked to NASH.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a2197chttps://doi.org/10.1158/2326-6066.30255493
View Full Paper
Ask AI
Bookmark
Share